Cargando…

Successful treatment of refractory lung adenocarcinoma harboring a germline BRCA2 mutation with olaparib: A case report

BACKGROUND: In recent years, targeted therapy and immunotherapy have become important treatment strategies for patients with non-small cell lung cancer (NSCLC). However, the clinical evidence for successful off-label use of targeted drugs for patients with NSCLC following progression on multiple lin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Li, Wang, Jing, Cui, Ling-Zhi, Wang, Kai, Yuan, Ming-Ming, Chen, Rong-Rong, Zhang, Li-Jiao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8464460/ https://www.ncbi.nlm.nih.gov/pubmed/34616818 http://dx.doi.org/10.12998/wjcc.v9.i25.7498

Ejemplares similares

A case report of a dramatic response to olaparib in a patient with metastatic pancreatic cancer harboring a germline BRCA2 mutation
por: Wang, Huan, et al.
Publicado: (2019)

Olaparib is effective for recurrent urothelial carcinoma with BRCA2 pathogenic germline mutation: first report on olaparib response in recurrent UC
por: Yang, Hong, et al.
Publicado: (2020)

Olaparib Treatment in a Patient with Advanced Gallbladder Cancer Harboring BRCA1 Mutation
por: Li, Xiaofen, et al.
Publicado: (2021)

Olaparib and somatic BRCA mutations
por: George, Angela, et al.
Publicado: (2017)

Pancreatic cancer patients with germline BRCA mutations can benefit from olaparib treatment
por: Mukherjee, Shibani, et al.
Publicado: (2020)

Cost-Effectiveness Analysis of Olaparib Maintenance Treatment for Germline BRCA-Mutated Metastatic Pancreatic Cancer
por: Li, Na, et al.
Publicado: (2021)

Response to olaparib in metastatic castration-resistant prostate cancer with germline BRCA2 mutation: a case report
por: Ma, Yi, et al.
Publicado: (2018)

Response to Olaparib in a Patient with Germline BRCA2 Mutation and Breast Cancer Leptomeningeal Carcinomatosis
por: Exman, Pedro, et al.
Publicado: (2019)

Exceptional Response to Olaparib and Pembrolizumab for Pancreatic Adenocarcinoma With Germline BRCA1 Mutation and High Tumor Mutation Burden: Case Report and Literature Review
por: Lundy, Joanne, et al.
Publicado: (2022)

Remarkable Response to Olaparib in a Patient with Combined Hepatocellular-Cholangiocarcinoma Harboring a Biallelic BRCA2 Mutation
por: Su, Yu-Li, et al.
Publicado: (2021)

Response of germline BRCA2-mutated advanced pancreatic acinar cell carcinoma to olaparib: A case report
por: Li, Mao, et al.
Publicado: (2018)

Treatment with olaparib monotherapy for BRCA2-mutated refractory intrahepatic cholangiocarcinoma: a case report
por: Cheng, Yuan, et al.
Publicado: (2018)

Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib
por: Hammel, P, et al.
Publicado: (2019)

Response of BRCA1-mutated gallbladder cancer to olaparib: A case report
por: Xie, Yuan, et al.
Publicado: (2016)

Excellent Response to Olaparib in a Patient with Metastatic Pancreatic Adenocarcinoma with Germline BRCA1 Mutation after Progression on FOLFIRINOX: Case Report and Literature Review
por: Pimenta, Jefferson Rios, et al.
Publicado: (2020)

Olaparib combined with immunotherapy for treating a patient with liver cancer carrying BRCA2 germline mutation: A case report
por: Zhao, Fengjiao, et al.
Publicado: (2020)

Favorable Response to Olaparib in a Patient with Cancer of Unknown Primary Carrying a Germline BRCA1 R71K Mutation
por: Jia, Xiaomeng, et al.
Publicado: (2021)

Treatment Options for Germline BRCA-Mutated Metastatic Pancreatic Adenocarcinoma
por: Grzelak, Doreen
Publicado: (2021)

Dramatic response to local radiotherapy in a refractory metastatic mediastinal yolk sac tumor patient harboring a germline BRCA2 frameshift mutation: a case report
por: Cheng, Xi, et al.
Publicado: (2022)

Olaparib effectively treats local recurrence of extrahepatic cholangiocarcinoma in a patient harboring a BRCA2-inactivating mutation: a case report
por: Li, Wenxin, et al.
Publicado: (2021)

Pancreatic mucinous cystadenocarcinoma in a patient harbouring BRCA1 germline mutation effectively treated with olaparib: A case report
por: Di Marco, Mariacristina, et al.
Publicado: (2020)

Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis
por: Im, Seock-Ah, et al.
Publicado: (2020)

Cost-Effectiveness Analysis of Maintenance Olaparib in Patients with Metastatic Pancreatic Cancer and a Germline BRCA1/2 Mutation Based on the POLO Trial
por: Zhan, Mei, et al.
Publicado: (2020)

Adjuvant Olaparib for Germline BRCA Carriers With HER2-Negative Early Breast Cancer: Evidence and Controversies
por: Morganti, Stefania, et al.
Publicado: (2023)

MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib
por: Whicker, Margaret E., et al.
Publicado: (2016)

Efficacy of Olaparib in Treatment-Refractory, Metastatic Breast Cancer with Uncommon Somatic BRCA Mutations Detected in Circulating Tumor DNA
por: Yoon, Jung-Ki, et al.
Publicado: (2023)

Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer
por: Rafii, Saeed, et al.
Publicado: (2017)

Clinical Activity and Safety of Cediranib and Olaparib Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma without BRCA Mutation
por: Kim, Joseph W., et al.
Publicado: (2021)

Metastatic lung adenocarcinoma with BRCA2 mutation and longstanding disease control on olaparib, developing triple negative breast adenocarcinoma with additional BRCA2 reversion mutation: a case report
por: del Giglio, Auro, et al.
Publicado: (2023)

BRCA2 reversion mutation confers resistance to olaparib in breast cancer
por: Yamamoto, Shinya, et al.
Publicado: (2023)

Successful Combination of Olaparib and (225)Ac-Dotatate in a Patient with Neuroendocrine Tumor G3 and BRCA Mutation
por: Kröcher, Anke, et al.
Publicado: (2023)

A narrative review of Safety management of 1 L platinum-based chemotherapy and maintenance olaparib in BRCA mutated advanced pancreatic cancer
por: Yao, Jiayu, et al.
Publicado: (2021)

Comparison of BRCA versus non-BRCA germline mutations and associated somatic mutation profiles in patients with unselected breast cancer
por: Chen, Bo, et al.
Publicado: (2020)

BRCA1 Reversion Mutation Confers Resistance to Olaparib and Camrelizumab in a Patient with Breast Cancer Liver Metastasis
por: Pan, Jia-Ni, et al.
Publicado: (2021)

Prolonged response on olaparib maintenance in metastatic pancreatic acinar cell carcinoma associated with a germline BRCA 2 mutation, revealed by severe panniculitis
por: Lelong, Margaux, et al.
Publicado: (2022)

Case report: olaparib use in metastatic lung adenocarcinoma with BRCA2 pathogenic variant
por: Soon Jian Hao, Jonathan, et al.
Publicado: (2022)

Case report: Olaparib as an experimental therapy in a BRCA2-mutated patient with metastatic ovarian adenocarcinoma that originated from liver cancer
por: Li, Caixia, et al.
Publicado: (2022)

The germline mutational landscape of BRCA1 and BRCA2 in Brazil
por: Palmero, Edenir Inêz, et al.
Publicado: (2018)

Overview on population screening for carriers with germline BRCA mutation in China
por: Lei, Huijun, et al.
Publicado: (2022)

Predisposition to Lung Adenocarcinoma in a Family Harboring the Germline EGFR V843I Mutation
por: Ohtsuka, Kouki, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_b4k7aqd0tman3bcqj60grjk406